Cyclin-dependent kinase 9

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

Retrieved on: 
Saturday, October 14, 2023
KRAS, SOC, BRM, NSCLC, Cyclin-dependent kinase 9, Development, AACR, Brain, Trial of the century, SMARCA2, MD, SMARCA4, CDK9, Biomarker, Hematological Cancer Research Investment and Education Act, Growth, Controlled Impact Demonstration, Bone marrow, Patient, Pharmaceutical industry, Medical device, Vaccine, PRB

and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA.

Key Points: 
  • and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA.
  • The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude’s CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789.
  • Initial clinical data from first three dose escalation cohorts (20, 40 and 80 mg QD) were reported.
  • We look forward to the translation of these preclinical results in clinical readouts planned for 2024,” said Peggy Sherle, Ph.D., Chief Scientific Officer of Prelude Therapeutics.

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Retrieved on: 
Thursday, June 29, 2023
Oncology, Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Drug development, FOR, Stifel, Cancer, OXPHOS, Eganelisib, Morgan Lewis, Cyclin-dependent kinase 9, Acute myeloid leukemia, Adenosine, Patient, Colorectal cancer, Infinity, Neoplasm, MEI, Letter, CDK9, Safety, Bone marrow, Holding company, Pharmaceutical industry, Vaccine

Our transaction with Infinity provides our shareholders the opportunity to benefit from the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline.

Key Points: 
  • Our transaction with Infinity provides our shareholders the opportunity to benefit from the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline.
  • We believe the benefits of the Infinity transaction are compelling for MEI shareholders:
    The combined company will have a diversified pipeline of three clinical-stage development programs.
  • All three clinical-stage development programs have the potential, in combination with current therapies, to overcome known resistance mechanisms.
  • The MEI Board recommends all MEI shareholders support the Infinity transaction TODAY.

MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Retrieved on: 
Tuesday, May 23, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cyclin-dependent kinase 9, Index, Failure, Diarrhea, Lymphoid leukemia, CDK, Bone marrow, Cancer, Pharmacokinetics, Biomarker, Aplastic anemia, Acute myeloid leukemia, Plasma, AML, BCL2, Patient, Nausea, Toxic leukoencephalopathy, Infrared spectroscopy correlation table, Venetoclax, Safety, Fatigue, Pharmaceutical industry

Dose escalation is continuing in the voruciclib and venetoclax combination arm in patients with R/R AML.

Key Points: 
  • Dose escalation is continuing in the voruciclib and venetoclax combination arm in patients with R/R AML.
  • The primary objectives of the study are to determine the safety and biologic effective dose of voruciclib monotherapy or voruciclib in combination with venetoclax.
  • Stage 2 of the study is evaluating voruciclib in combination with standard dose venetoclax in patients with R/R AML.
  • Part 2 of the study is currently evaluating the combination of voruciclib and venetoclax in patients with R/R AML.

MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Workforce, Commercialization, Lymphoid leukemia, Venetoclax, Calendar, Cancer, Acute myeloid leukemia, Kyowa Kirin, Development, AML, Patient, Investment, PMDA, Colorectal cancer, Infinity, Cell cycle, Bone marrow, Neoplasm, MEI, Research, CDK9, Cyclin-dependent kinase 9, Safety, Pharmaceutical industry, Cryptocurrency

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2023, and highlighted recent corporate events.

Key Points: 
  • MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2023, and highlighted recent corporate events.
  • In February 2023, MEI Pharma and Infinity Pharmaceuticals announced a definitive merger agreement for an all-stock transaction pursuant to which Infinity will become a wholly owned subsidiary of MEI Pharma.
  • Research and development expenses were $15.1 million for the quarter ended March 31, 2023, compared to $22.3 million for the quarter ended March 31, 2022.
  • MEI recognized revenue of $5.9 million for the quarter ended March 31, 2023, compared to $9.7 million for the quarter ended March 31, 2022.

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 15, 2023
Research, AACR, Glioma, SMARCA2, CDK9, Lung cancer, CDK4, Venetoclax, Head, File, Patient, Toxicity, BTK, SMARCA4, Breast, Azacitidine, Bone marrow, Safety, Cyclin-dependent kinase 9, Hematological Cancer Research Investment and Education Act, BeiGene, Pharmaceutical industry, Beauty salon

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.   

Key Points: 
  • Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024
    WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.
  • “We made considerable progress in 2022, including the filing and acceptance of two new INDs for our next generation CDK4/6 inhibitor and our first-in-class, highly selective SMARCA2 degrader.
  • Initial data from PRT2527 and PRT1419 demonstrate encouraging safety, favorable pharmacokinetic and pharmacodynamic profiles in solid tumors, and support continued advancement in hematological cancers.
  • Title: A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors.

MEI Pharma Initiates Strategic Realignment

Retrieved on: 
Monday, December 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ATP, PI3K, Cyclin, Lymphoid leukemia, Myc, Cell proliferation, Adenosine triphosphate, Calendar, Bevacizumab, Patient, CDK9, Neoplasm, Cancer, Mitochondrion, Wind, Cyclin-dependent kinase 9, ASCO, Kyowa Hakko Kirin, FDA, Woman, MYC, Investment, COVID-19, Colorectal cancer, Growth, AML, KRAS, Lymphatic system, Nature, Safety, Clinical trial, Failure, Workforce, OXPHOS, Acute myeloid leukemia, Doctor of Philosophy, Marketing, VEGF, Regulation, MEI, Pharmaceutical industry, Medical imaging

As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344.

Key Points: 
  • As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344.
  • The company further announced that it has engaged Torreya Partners as financial advisor to help explore additional strategic opportunities.
  • We intend to continue development of our earlier-stage clinical assets, streamline MEIs operations towards these efforts, and consider additional strategic opportunities, said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company focused on developing potential new therapies for cancer.

SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations

Retrieved on: 
Thursday, September 29, 2022
Bioequivalence, Therapy, PK, WT1, Sex, COVID-19, MD, SLS, Â, Society, NEW, Company, Senior, SOHO, PH, Patient, Memorial Sloan Kettering Cancer Center, Hematology-Oncology and Stem Cell Transplantation Research Center, Terminology, Annual report, Cyclin-dependent kinase 9, Drug development, NASDAQ, GLOBE, SEC, Lymphoma, Drug, Rat, GPS, CDK9, Human, Pharmaceutical industry, Greater China

The bioequivalence study was performed to evaluate the effect of different formulations on GFH009s preclinical pharmacokinetic (PK) profile.

Key Points: 
  • The bioequivalence study was performed to evaluate the effect of different formulations on GFH009s preclinical pharmacokinetic (PK) profile.
  • Dr. Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS, presented the findings at this years Meeting of the Society of Hematologic Oncology (SOHO) in a poster titled Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • These statements include, without limitation, statements related to preclinical data for GFH009, plans for further development of GFH009, and the potential for GFH009 as a drug development candidate.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Drug Pipeline Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 14, 2022
Health, Pharmaceutical, CDK9, Cyclin-dependent kinase 9, Therapy, Pharmaceutical industry, Fine chemical, Cyclin-dependent kinase 4

The "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cyclin-Dependent Kinase 9 (CDK9) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

CDK9 Inhibitor Pipeline Market Report 2022: Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022
Health, Pharmaceutical, Alvocidib, Merck & Co., Acute myeloid leukemia, III, CDK5, Cyclin T1, CTD, KDA, RNA polymerase II, Clinical trial, CDK, Discovery, Neoplasm, Cyclin-dependent kinase 9, Gene expression, ATP, II, Cancer, Cell cycle, Ligand Pharmaceuticals, SCH, Gene, Protein kinase, MYC, Pharmacopoeia, News, CDK2, Blockade, CDK9, Therapy, Association, Schering-Plough, RNA, Chronic lymphocytic leukemia, CDK1, Fertilizer, Vaccine, Pharmaceutical industry

This "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.

Key Points: 
  • This "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.
  • There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.
  • 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.
  • The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e.

Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Biology, Cell Cycle, Proteins, Transcription factors, Myc, Oncogenes, Cyclin-dependent kinase 9, Zotiraciclib

ET

Key Points: 
  • ET
    Kronos Bio initiated a Phase 1/2 clinical trial of KB-0742 in patients with advanced solid tumors or non-Hodgkin lymphoma earlier this year.
  • KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in development for the treatment of MYC-amplified solid tumors.
  • Kronos Bio leverages its SMM screening platform to conduct high-throughput screens against traditionally undruggable target proteins, in particular transcription factors.
  • The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.